Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.57 USD
-0.01 (-0.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.50 -0.07 (-0.27%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum B VGM
Balance Sheet
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 73 | 86 | 94 | 98 | 185 |
Receivables | 36 | 35 | 30 | 24 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 46 | 40 | 36 | 46 | 22 |
Other Current Assets | 8 | 9 | 8 | 9 | 4 |
Total Current Assets | 163 | 170 | 169 | 177 | 234 |
Net Property & Equipment | 46 | 48 | 48 | 51 | 51 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 0 | 0 | 0 |
Intangibles | 12 | 82 | 90 | 100 | 15 |
Deposits & Other Assets | 19 | 17 | 20 | 15 | 7 |
Total Assets | 271 | 349 | 348 | 366 | 331 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 9 | 8 | 9 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 19 | 18 | 15 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 4 | 13 | 0 |
Total Current Liabilities | 31 | 28 | 30 | 37 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 6 | 10 | 12 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 24 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58 | 64 | 60 | 93 | 42 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 90 | 81 | 67 | 55 | 49 |
Retained Earnings | 128 | 211 | 226 | 221 | 245 |
Other Equity | -6 | -6 | -6 | -5 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 212 | 286 | 287 | 272 | 288 |
Total Liabilities & Shareholder's Equity | 271 | 349 | 348 | 366 | 331 |
Total Common Equity | 212 | 286 | 287 | 272 | 288 |
Shares Outstanding | 14.60 | 14.60 | 14.40 | 14.20 | 14.20 |
Book Value Per Share | 14.54 | 19.56 | 19.94 | 19.18 | 20.31 |
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 73 | 71 | 65 | 80 |
Receivables | NA | 36 | 35 | 37 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 46 | 44 | 43 | 41 |
Other Current Assets | NA | 8 | 8 | 8 | 9 |
Total Current Assets | NA | 163 | 157 | 152 | 160 |
Net Property & Equipment | NA | 46 | 46 | 48 | 49 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 1 | 2 | 2 |
Intangibles | NA | 12 | 76 | 78 | 80 |
Deposits & Other Assets | NA | 19 | 19 | 19 | 18 |
Total Assets | NA | 271 | 328 | 329 | 339 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 8 | 8 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 21 | 20 | 16 | 20 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 31 | 28 | 23 | 29 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 2 | 3 | 4 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 58 | 58 | 55 | 61 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 90 | 86 | 82 | 83 |
Retained Earnings | NA | 128 | 191 | 198 | 200 |
Other Equity | NA | -6 | -7 | -6 | -6 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 212 | 270 | 274 | 278 |
Total Liabilities & Shareholder's Equity | NA | 271 | 328 | 329 | 339 |
Total Common Equity | 0 | 212 | 270 | 274 | 278 |
Shares Outstanding | 14.80 | 14.60 | 14.60 | 14.70 | 14.70 |
Book Value Per Share | 0.00 | 14.54 | 18.53 | 18.64 | 18.88 |